Vasco C Romão

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5078532/publications.pdf

Version: 2024-02-01

393982 301761 1,791 56 19 39 citations g-index h-index papers 60 60 60 2647 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Annals of the Rheumatic Diseases, 2020, 79, 3-18.	0.5	307
2	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet, The, 2021, 397, 305-317.	6.3	145
3	Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Realâ€Life, International Systemic Lupus Erythematosus Cohort. Arthritis Care and Research, 2015, 67, 1180-1185.	1.5	125
4	Human blood T $<$ sub $>$ fr $<$ /sub $>$ cells are indicators of ongoing humoral activity not fully licensed with suppressive function. Science Immunology, 2017, 2, .	5.6	119
5	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nature Medicine, 2022, 28, 1256-1268.	15.2	105
6	The Ratio of Blood T Follicular Regulatory Cells to T Follicular Helper Cells Marks Ectopic Lymphoid Structure Formation While Activated Follicular Helper T Cells Indicate Disease Activity in Primary Sjögren's Syndrome. Arthritis and Rheumatology, 2018, 70, 774-784.	2.9	94
7	Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity?. Immunologic Research, 2014, 60, 289-310.	1.3	91
8	B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis. PLoS ONE, 2017, 12, e0182927.	1.1	72
9	Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?. BMC Medicine, 2013, 11, 17.	2.3	71
10	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals of the Rheumatic Diseases, 2022, 81, 970-978.	0.5	49
11	Etiology and Risk Factors for Rheumatoid Arthritis: A State-of-the-Art Review. Frontiers in Medicine, 2021, 8, 689698.	1.2	47
12	Clinical features and long-term outcomes of systemic lupus erythematosus: comparative data of childhood, adult and late-onset disease in a national register. Rheumatology International, 2016, 36, 955-960.	1.5	44
13	Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?. Arthritis Research and Therapy, 2017, 19, 239.	1.6	38
14	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. Nature Reviews Rheumatology, 2021, 17, 177-184.	3.5	35
15	Sjögren's syndrome: state of the art on clinical practice guidelines. RMD Open, 2018, 4, e000789.	1.8	34
16	A Multicenter Retrospective Analysis Evaluating Performance of Synovial Biopsy Techniques in Patients With Inflammatory Arthritis. Arthritis and Rheumatology, 2018, 70, 702-710.	2.9	32
17	Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups. Arthritis Research and Therapy, 2018, 20, 265.	1.6	29
18	Characterization of damage in Portuguese lupus patients: analysis of a national lupus registry. Lupus, 2015, 24, 256-262.	0.8	26

#	Article	IF	CITATIONS
19	Neurologic Manifestations of the Antiphospholipid Syndrome — an Update. Current Neurology and Neuroscience Reports, 2021, 21, 41.	2.0	26
20	Association between age at disease onset of anti-neutrophil cytoplasmic antibody–associated vasculitis and clinical presentation and short-term outcomes. Rheumatology, 2021, 60, 617-628.	0.9	22
21	Anti-TNF Drugs for Chronic Uveitis in Adults—A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Medicine, 2019, 6, 104.	1.2	21
22	Efficacy and safety of intravitreal antiâ€ŧumour necrosis factor drugs in adults with nonâ€ɨnfectious uveitis – a systematic review. Acta Ophthalmologica, 2018, 96, e665-e675.	0.6	20
23	Comparative Effectiveness of Tocilizumab and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from the Rheumatic Diseases Portuguese Register, Reuma.pt. BioMed Research International, 2015, 2015, 1-13.	0.9	19
24	Rheumatology practice amidst the COVID-19 pandemic: a pragmatic view. RMD Open, 2020, 6, e001314.	1.8	19
25	Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder?. Frontiers in Medicine, 2019, 6, 144.	1.2	18
26	Treatment-resistant synovitis and radiographic progression are increased in elderly-onset rheumatoid arthritis patients: findings from a prospective observational longitudinal early arthritis cohort study. Seminars in Arthritis and Rheumatism, 2020, 50, 735-743.	1.6	15
27	Educational needs and preferences of young European clinicians and physician researchers working in the field of rheumatology. RMD Open, 2016, 2, e000240.	1.8	14
28	T Follicular Regulatory Cells Are Decreased in Patients With Established Treated Rheumatoid Arthritis With Active Disease: Comment on the Article by Liu etÂal. Arthritis and Rheumatology, 2018, 70, 1893-1895.	2.9	14
29	Efficacy, Safety, and Sample Quality of Ultrasoundâ€Guided Synovial Needle Biopsy in Clinical Practice and Research: A Prospective Observational Study. Arthritis Care and Research, 2020, 72, 1497-1505.	1.5	14
30	Post-COVID-19 syndrome in patients with primary Sjögren's syndrome after acute SARS-CoV-2 infection. Clinical and Experimental Rheumatology, 2021, 39, 57-65.	0.4	13
31	No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit. Annals of the Rheumatic Diseases, 2021, 80, e22-e22.	0.5	12
32	EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology. Annals of the Rheumatic Diseases, 2022, 81, 1640-1646.	0.5	12
33	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. Clinical and Experimental Rheumatology, 2022, 40, 3-11.	0.4	12
34	Overactive bladder symptom bother and health-related quality of life in patients with systemic lupus erythematosus and primary Sjögren syndrome. Lupus, 2019, 28, 27-33.	0.8	10
35	Celastrol Efficacy by Oral Administration in the Adjuvant-Induced Arthritis Model. Frontiers in Medicine, 2020, 7, 455.	1.2	10
36	A Non-Infectious Uveitis Multidisciplinary Clinic in a Tertiary Referral Center: Clinical Impact and Added Value. Journal of Multidisciplinary Healthcare, 2021, Volume 14, 695-704.	1.1	8

#	Article	IF	CITATIONS
37	A COVID-19 Outbreak in a Rheumatology Department Upon the Early Days of the Pandemic. Frontiers in Medicine, 2020, 7, 576162.	1.2	7
38	Efficacy and Safety of Vaccination in Pediatric Patients with Systemic Inflammatory Rheumatic Diseases: a systematic review of the literature. Acta Reumatológica Portuguesa, 2017, 42, 8-16.	0.2	7
39	Synovial heterogeneity in rheumatoid arthritis: the key for rational patient stratification?. Acta Reumatol \tilde{A}^3 gica Portuguesa, 2015, 40, 6-8.	0.2	5
40	Saber Tibia in Paget's Disease of Bone. New England Journal of Medicine, 2014, 371, 2417-2417.	13.9	4
41	Erythema elevatum diutinum in Crohn's disease-associated Spondyloarthritis - a rare vasculitis, an unusual association. Acta Reumatológica Portuguesa, 2017, 42, 324-328.	0.2	4
42	Sj \tilde{A} ¶gren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. Clinical and Experimental Rheumatology, 2022, 40, 103-112.	0.4	3
43	Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases. Clinical and Experimental Rheumatology, 2022, 40, 32-39.	0.4	3
44	OO7â€fRandomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy. Rheumatology, 2020, 59, .	0.9	1
45	Response to: â€The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli <i>et al</i> . Annals of the Rheumatic Diseases, 2021, 80, e76-e76.	0.5	1
46	Late presentation of macrodystrophia lipomatosa—a rare, impressive diagnosis. Rheumatology, 2021, 61, 469-470.	0.9	1
47	Clinical and ultrasonographic features of erythema nodosum in Behçet's disease. Rheumatology, 2022, 61, e254-e254.	0.9	1
48	Angiotensin-Converting Enzyme Activity May Predict Disease Severity in Psoriasis. Rheumato, 2022, 2, 15-23.	0.2	1
49	$01.06 \hat{a} \in$ B-cell phenotype and igd-cd27- memory b cells are affected by tnf-inhibitors and tocilizumab treatment in rheumatoid arthritis. , 2017, , .		0
50	Reply. Arthritis and Rheumatology, 2018, 70, 1355-1356.	2.9	0
51	Elderly-onset rheumatoid arthritis is a unique disease subset associated with poor overall outcomes: Response to the letter by Haroon and Ayamer. Seminars in Arthritis and Rheumatism, 2020, 51, e11-e12.	1.6	0
52	Loss to follow-up in registries of rheumatic patients treated with biologics: a potential information bias in assessing pharmacovigilance and efficacy outcomes. Acta Reumatol \tilde{A}^3 gica Portuguesa, 2019, 44, 281-287.	0.2	0
53	Post-COVID-19 syndrome in patients with primary Sj \tilde{A} ¶gren's syndrome after acute SARS-CoV-2 infection. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
54	Off-label use of mycophenolate mofetil in the treatment of rare and complex rheumatic connective tissue diseases Clinical and Experimental Rheumatology, 2022, , .	0.4	0

#	Article	IF	CITATIONS
55	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET Clinical and Experimental Rheumatology, 2022, , .	0.4	O
56	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison Clinical and Experimental Rheumatology, 2022, , .	0.4	0